mk-6240

Cognitive Disorder

NYU Langone HealthUNKNOWNPhase 3Active

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 73/ 100

Competitive context

131 Active assets in the Cognitive Disorder cohort.

Asset / Sponsor	Phase	Rating
Nicotine University of Southern California	Phase 2	BBB
Oxybutynin University of Alberta	Phase 4	BBB
Quetiapine Emory University	Phase 4	BB
Rivastigmine VA Office of Research and Development	Phase 4	BB
Metformin Fudan University	Phase 4	BB

View all 50 →

Same molecule, other indications

mk-6240 is also rated in:

Alzheimer diseaseActive

BB

Indicative · Phase 3

65 / 100

Down syndromeActive

B

Indicative · Phase 3

60 / 100

type 2 diabetes mellitusActive

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.